Tag: nonalcoholic steatohepatitis
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
1. Obeticholic acid, a farnesoid X receptor agonist, prompts fibrosis improvement in patients with non-alcoholic steatohepatitis (NASH)
Evidence Rating Level: 1 (Excellent)
Non-alcoholic steatohepatitis (NASH) is an increasingly common cause of chronic liver disease...
1. Delivery of a hybridized form of glucagon and the thyroid hormone T3 (G/T3) improved signs of metabolic syndromes including dyslipidemia and nonalcoholic steatohepatitis (NASH).
2. Unlike treatment with T3 alone, G/T3 improved pathological signs without causing adverse effects on cardiac function and bone integrity.
Evidence Rating Level: 1 (Excellent) ...